PROT Joint Venture Agreement, Stock Update On ISIS,PDLI - PennyToBuck.com

Aug. 17, 2010 - PRLog -- Proteonomix, Inc. (PROT.OB) a biotechnology company, engages in the development of stem cell therapies primarily for the treatment of diabetes and cardiac therapy, as well as offers cosmeceutical products.

The stem cell therapy involves the introduction of healthy new stem cells to repair and replace damaged or lost cells. It offers product for the treatment of anti-aging and damaged skin.

**Proteonomix, Inc. announced today that it has executed a joint venture agreement with a group of investors that will create a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.).

The Investor Group has committed to invest $5 million on or before September 10, 2010.

The Joint Venture company, XGen Medical LLC (”XGen”), a Nevis Island limited liability company, will be owned 51% by Proteonomix and 49% by the Investor Group.

Due to confidentiality and competitive reasons, the Investor Group has requested to remain anonymous for the present. The Investor Group is not related directly and/or indirectly to the Company, its management, its board of directors and/or its current shareholders.

For more information about this company please visit http://www.proteonomix.com





Isis Pharmaceuticals, Inc.  is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.

The Company has successfully commercialized the world’s first antisense drug and has 23 drugs in development.

Isis’ drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.

Isis’ partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.

Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.

Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.

As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of approximately 1,600 issued patents worldwide.

**”We have been very successful with our partnerships, bringing in more than $55 million in cash this year, including $35 million from our recent partnership with GSK. Already this year, we have achieved the first milestone under our collaboration with GSK and earned an additional $5 million, one of the factors that has allowed us to improve our guidance. Also contributing to our improved financial performance is revenue we received as a result of Regulus’ newly formed alliance with sanofi-aventis and the milestone payments we earned from BMS and Achaogen. Our creation of Regulus with our partners at Alnylam to explore the exciting new area of microRNAs is an example of our continuing commitment and success in expanding our antisense technology platform,” said B. Lynne Parshall, COO and CFO of Isis.

For more information about this company please visit http://www.isispharm.com





PDL BioPharma, Inc.  pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases.

PDL is focused on maximizing the value of its antibody humanization patents and related assets.

The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents that expire in late 2014.

**PDL BioPharma, Inc. announced it has received a facsimile letter from Genentech asserting that Avastin(R), Herceptin(R), Lucentis(R) and Xolair(R) (the Genentech Products) do not infringe supplementary protection certificates (SPCs) granted by various countries in Europe to PDL and is seeking a response from PDL to these assertions.

The letter was received at 4:00 pm PDT on Wednesday, August 11, 2010.

The letter does not suggest that the Genentech Products do not infringe PDL’s United States patents to the extent that such Genentech Products are made, used or sold in the United States, including Genentech Products that are made in the United States and sold elsewhere. As a result, PDL anticipates that Genentech will continue to make royalty payments on such activities.

For more information about this company please visit http://www.pdl.com


For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.  Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)